Edwards Lifesciences Corporation (ETR:EWL)

Market Cap	43.35B +5.6%
Revenue (ttm)	5.47B +14.1%
Net Income	950.73M -73.8%
EPS	1.63 -73.2%
Shares Out	n/a
PE Ratio	45.59
Forward PE	28.62
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	74.94
Previous Close	75.26
Day's Range	74.94 - 74.94
52-Week Range	62.00 - 76.02
Beta	0.87
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 23, 2026

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aor...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1958
• Employees: 16,000
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: EWL

Financial Performance

In 2025, Edwards Lifesciences's revenue was $6.07 billion, an increase of 11.55% compared to the previous year's $5.44 billion. Earnings were $1.07 billion, a decrease of -74.28%.

Financial numbers in USD